VDV1 Attenuated Strain Genetic Homogeneity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dengue vaccines lack effectiveness in providing comprehensive protection against all four dengue virus serotypes, and there is a risk of severe disease due to heterogeneity in live attenuated virus strains used in existing vaccines, which can lead to in vitro or in vivo selection of virulent strains.
Innovation Solution
Development of VERO-Derived Dengue serotype 1 virus (VDV1) strains through sanitization and passage on VERO cells, which maintains attenuation and immunogenic features while reducing genetic heterogeneity, ensuring a homogeneous and stable vaccine candidate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live attenuated virus strains are used in dengue vaccines, then immunogenicity and ability to induce immune response are improved, but genetic heterogeneity increases leading to selection of virulent strains
Solution Approach 1:
The patent applies homogeneity by using a single, well-defined attenuated virus strain (DVV1) with a specific deletion mutation in the E-gene (amino acids 222-237). This ensures genetic uniformity across all vaccine doses, preventing the genetic heterogeneity that would otherwise lead to selection of virulent strains while maintaining consistent immunogenicity.
Solution Approach 2:
The patent extracts the problematic heterogeneity by removing the variable regions through site-directed mutagenesis. Specifically, a defined deletion mutation (amino acids 222-237 in the E-gene) is introduced to create a stable, homogeneous attenuated strain that eliminates the risk of genetic variation while preserving immunogenicity.
2Adaptability or versatility
If dengue vaccines provide comprehensive protection against all four serotypes, then coverage is improved, but complexity of vaccine composition increases
Solution Approach 1:
The patent applies segmentation by developing separate monovalent vaccines for each of the four dengue serotypes. Each vaccine contains a single attenuated strain specific to one serotype, simplifying the composition and manufacturing of each individual vaccine while allowing flexible combination strategies to achieve comprehensive coverage.
Solution Approach 2:
The patent applies universality by creating a platform technology where the same vaccine formulation approach and attenuation strategy can be applied to all four dengue serotypes. The DVV1 strain and its derivation methodology serve as a universal model that can be adapted to generate vaccines for any serotype, simplifying development across multiple products.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
VDV1 strains induce a specific humoral immune response with neutralizing antibodies, providing effective prophylactic immunization and reducing the risk of severe disease by ensuring genetic stability and homogeneity, thus addressing the limitations of existing dengue vaccines.
Implementation Method 1
VDV1 strains induce a specific humoral immune response with neutralizing antibodies
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 viruse) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.